Risk of reliance on sales of Opdivo
First written in FY2016. 3 of 8 entries say "Worsened", first in FY2017. Latest entry: FY2025.
Ono Pharmaceutical moved to the "Worse" side of this theme in 2025, 5 years after the typical company in this theme (2020).
The whole theme swung hardest in 2017: 4 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Softened".
- FY2025SoftenedAnnual report
「Revenue from “Opdivo intravenous infusion” and “royalties related to anti-PD-1/PD-L1 antibodies” accounted for approximately the mid-50% range of total revenue in the fiscal year ended March 2025.」
Dependence on Opdivo and royalties related to anti-PD-1/PD-L1 antibodies was stated to have declined from approximately the mid-60% range in the previous fiscal year to approximately the mid-50% range. - FY2024RestatedAnnual report
「Revenue from “Opdivo intravenous infusion” and “royalties related to anti-PD-1/PD-L1 antibodies” accounted for approximately the mid-60% range of total revenue in the fiscal year ended March 2024.」
Dependence on Opdivo and royalties related to anti-PD-1/PD-L1 antibodies was stated to be approximately in the mid-60% range, as in the fiscal year ended March 2023, reconfirming the concentration at this level. - FY2023WorsenedAnnual report
「Revenue from Opdivo intravenous infusion and royalties related to anti-PD-1/PD-L1 antibodies accounted for the mid-60% range of the Group’s total revenue in the fiscal year ended March 2023.」
Dependence on Opdivo and royalties related to anti-PD-1/PD-L1 antibodies rose from approximately 60% previously to the mid-60% range. - FY2022RestatedAnnual report
「Revenue from Opdivo intravenous infusion and royalties related to anti-PD-1/PD-L1 antibodies accounted for approximately 60% of the Group’s total revenue in the fiscal year ended March 2022.」
Dependence on Opdivo and royalties related to anti-PD-1/PD-L1 antibodies was reaffirmed at approximately 60% of revenue, unchanged from the previous disclosure. - FY2020WorsenedAnnual report
「Revenue from Opdivo intravenous infusion and royalties related to anti-PD-1 antibodies accounted for approximately 60% of the Group’s total revenue in the fiscal year ended March 2020.」
The disclosed dependence expanded from approximately 50% of revenue from Opdivo-related sources to approximately 60% from Opdivo and royalties related to anti-PD-1 antibodies. - FY2018RestatedAnnual report
「Revenue from Opdivo intravenous infusion, including royalty income, accounted for approximately 50% of the Group’s total pharmaceutical revenue in the fiscal year ended March 2018, and further sales growth is expected.」
Dependence on Opdivo-related revenue remained approximately 50% in the fiscal year ended March 2018, reaffirming the same level of concentration as in the previous fiscal year. - FY2017WorsenedAnnual report
「Revenue from Opdivo intravenous infusion, including royalty income, accounted for approximately 50% of the Group’s total pharmaceutical revenue in the fiscal year ended March 2017, and further sales growth is expected.」
Dependence on Opdivo-related revenue is quantified as having increased from approximately 20% in the fiscal year ended March 2016, as previously disclosed, to approximately 50% in the fiscal year ended March 2017. - FY2016First statedAnnual report
「Revenue from Opdivo intravenous infusion, including royalty income, accounted for approximately 20% of the Group’s total pharmaceutical revenue in the fiscal year ended March 2016, and further sales growth is expected.」
The disclosure quantifies Opdivo-related revenue as approximately 20% of total revenue in the fiscal year ended March 2016 and describes the risk of lower revenue due to drug price revisions, competing products, patent expirations and other factors.